Squamous NSCLC Treatments Incorporating Immunotherapy Combinations
This roundtable series considers the use of immunotherapy-based combinations as treatment for non–small cell lung cancer, regardless of the patient’s PD-L1 expression, as discussed by participants at virtual live events.
Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLC
June 22nd 2022During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.
Advanced Squamous NSCLC Survival Improved With Chemoimmunotherapy Regardless of PD-L1 Expression
July 20th 2022During a live virtual event, Adam M. Schoenfeld, MD, discussed results of the KEYNOTE-407 trial of patients with advanced squamous non–small cell lung cancer in terms of PD-L1 expression. This is the second of 2 articles based on this event.
Reviewing 3-Year Updated Data From CheckMate 9LA for NSCLC
November 28th 2022During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed 3-year data on overall survival and subgroup analysis for the CheckMate 9LA trial of ipilimumab, nivolumab, and 2 cycles of chemotherapy.
Patient Selection Considerations for CheckMate 9LA Regimen in NSCLC
December 14th 2022During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed with participants which patients are candidates for chemoimmunotherapy for advanced non–small cell lung cancer. This is the second of 2 articles based on this event.
